Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic

BACKGROUND: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. RESEARCH DESIGN AND METHODS: Using a previously published combined Markov-decision tree model adapted for the Dominican Republic, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality-of-life inputs derived from the published literature and national surveillance data. Scenario analyses that included variations in the incidence of COVID-19 and sensitivity analyses were conducted to assess uncertainty. RESULTS: Compared to no vaccination, the vaccination strategy targeting adults aged ≥65 years and the high-risk population was estimated to prevent 9,272 symptomatic cases, 9,184 outpatient cases, 88 hospitalizations, 239 lost quality-adjusted life-years (QALYs), and three deaths, translating to total direct and societal cost savings of US$11,064,184 and US$12,662,370, respectively. Expanding vaccination to adults aged ≥60 years and high-risk individuals aged 18-59 years further increased public health and economic benefits. CONCLUSIONS: Implementing an adapted COVID-19 vaccine strategy for high-risk and adults aged ≥65 in the Dominican Republic is expected to be cost-saving, with broader age group coverage yielding even greater benefits.

Authors

Institutions

Publication Details

Journal
Expert Review of Vaccines
Published
2026-06-26
DOI
https://doi.org/10.1080/14760584.2026.2694383
Primary Topic
COVID-19 epidemiological studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic

Elena Aruffo, Carlos Fernando Mendoza, Marcel Marcano-Lozada, Juan José Baldi-Castro et al.
Expert Review of Vaccines
COVID-19 epidemiological studies
article

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic

Elena Aruffo, Carlos Fernando Mendoza, Marcel Marcano-Lozada, Juan José Baldi-Castro, Iustina Chirila, Karen Villamil-Herrera, Leo Alejandro Barrantes, Benjamin Yarnoff, Moe H Kyaw
article en

Abstract

BACKGROUND: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. RESEARCH DESIGN AND METHODS: Using a previously published combined Markov-decision tree model adapted for the Dominican Republic, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality-of-life inputs derived from the published literature and national surveillance data. Scenario analyses that included variations in the incidence of COVID-19 and sensitivity analyses were conducted to assess uncertainty. RESULTS: Compared to no vaccination, the vaccination strategy targeting adults aged ≥65 years and the high-risk population was estimated to prevent 9,272 symptomatic cases, 9,184 outpatient cases, 88 hospitalizations, 239 lost quality-adjusted life-years (QALYs), and three deaths, translating to total direct and societal cost savings of US$11,064,184 and US$12,662,370, respectively. Expanding vaccination to adults aged ≥60 years and high-risk individuals aged 18-59 years further increased public health and economic benefits. CONCLUSIONS: Implementing an adapted COVID-19 vaccine strategy for high-risk and adults aged ≥65 in the Dominican Republic is expected to be cost-saving, with broader age group coverage yielding even greater benefits.

Expert Review of VaccinesVol. 25(1)
Ithaka Harbors (US), Pfizer (United States) (US), Universidad de Costa Rica (CR)
Pfizer
Openalex Percentile: Top 8%
COVID-19 epidemiological studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.